Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology

被引：0

作者：

Hayashi, Toshinobu ^{[1
]}

Yamamoto, Shun ^{[2
]}

Miyata, Yoshiharu ^{[3
]}

Takeda, Masayuki ^{[4
]}

Abe, Masakazu ^{[5
]}

Wada, Makoto ^{[6
]}

Iino, Keiko ^{[7
]}

Akechi, Tatsuo ^{[8
]}

Imamura, Chiyo K. ^{[9
]}

Okuyama, Ayako ^{[10
]}

Ozawa, Keiko ^{[11
]}

Kim, Yong-Il ^{[12
]}

Sasaki, Hidenori ^{[13
]}

Satomi, Eriko ^{[14
]}

Tanaka, Ryuhei ^{[15
]}

Nakajima, Takako Eguchi ^{[16
]}

Nakamura, Naoki ^{[17
]}

Nishimura, Junichi ^{[18
]}

Noda, Mayumi ^{[19
]}

Hayashi, Kazumi ^{[20
]}

Higashi, Takahiro ^{[21
]}

Boku, Narikazu ^{[22
]}

Matsumoto, Koji ^{[23
]}

Matsumoto, Yoko ^{[24
]}

Okita, Kenji ^{[25
]}

Yamamoto, Nobuyuki ^{[26
]}

Aogi, Kenjiro ^{[27
]}

Iihara, Hirotoshi ^{[28
]}

机构：

[1] Fukuoka Univ, Fac Pharmaceut Sci, Dept Emergency & Disaster Med Pharm, 8-19-1,Nanakuma,Jonan Ku, Fukuoka, Japan

[2] Natl Canc Ctr, Dept Head & Neck, Esophageal Med Oncol, Tokyo, Japan

[3] Kobe Univ, Dept Artificial Intelligence & Digital Hlth Sci, Grad Sch Med, 7-1-48 Minatojimaminamimachi,Chuo Ku, Kobe, Japan

[4] Nara Med Univ, Dept Epidemiol, 840 Shijo Cho, Kashihara, 6348521, Japan

[5] Hamamatsu Univ Sch Med, Dept Surg, 1-20-1 Handayama,Chuo Ku, Hamamatsu, Shizuoka 4313192, Japan

[6] Osaka Int Canc Inst, Dept Hematol, 3-1-69 Chuo Ku, Osaka, Osaka 5418567, Japan

[7] Natl Coll Nursing, Dept Adult Nursing, 1-2-1,Umezono, Kiyose, Tokyo 2048575, Japan

[8] Nagoya City Univ, Grad Sch Med Sci, Dept Psychiat & Cognit Behav Med, 1 Kawasumi,Mizuho Cho,Mizuho Ku, Nagoya 4678601, Japan

[9] Showa Univ, Adv Canc Translat Res Inst, 1-5-8 Hatanodai,Shinagawa Ku, Tokyo 1428555, Japan

[10] St Lukes Int Univ, Grad Sch Nursing Sci, 10-1 Akashi Cho,Chuo ku, Tokyo 1040044, Japan

[11] Natl Canc Ctr, Inst Canc Control, Div Survivorship, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan

[12] Yodogawa Christians Hosp, Div Med Oncol, 1-7-50 Kunijima,Higasiyodogawa Ku, Osaka, Osaka 5330024, Japan

[13] Fukuoka Univ, Div Med Oncol Hematol & Infect Dis, 7-45-1,Nanakuma,Jonan Ku, Fukuoka 8140180, Japan

[14] Natl Canc Ctr, Dept Palliat Med, 5-1-1 Tsukiji,Chuo Ku, Tokyo 1040045, Japan

[15] Saitama Med Univ, Int Med Ctr, Dept Pediat Hematol & Oncol, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan

[16] Kyoto Univ, Grad Sch Med, Grad Sch Med, 54 Kawahara Cho,Shogoin,Sakyo ku, Kyoto 6068507, Japan

[17] St Marianna Univ, Dept Microbiol, 2-16-1,Sugao, Miyamae, Kawasaki 2168511, Japan

[18] Osaka Int Canc Inst, Dept Gastroenterol Surg, 3-1-69, Osaka 5418567, Japan

[19] Nonprofit Org Sasaeau KaiAlpha, 518-7 Kawado Cho,Chuo Ku, Chiba, Chiba 2600802, Japan

[20] Jikei Univ, Sch Med, Sch Med, Tokyo, Japan

[21] Univ Tokyo, Dept Hlth Serv Res, 7-3-1 Hongo,Bunkyo Ku, Tokyo 1130033, Japan

[22] Univ Tokyo, Inst Med Sci Hosp, Dept Oncol & Gen Med, 4-6-1 Shiroganedai,Minato ku, Tokyo 1088639, Japan

[23] Hyogo Canc Ctr, Div Diagnost Radiol, 13-70 Kitaoji Cho, Akashi, Hyogo 6730021, Japan

[24] Nonprofit Org Ehime Canc Support Orange No Kai, 3-8-24 Furukawaminami, Matsuyama, Ehime 7900943, Japan

[25] Otaru Ekisaikai Hosp, Dept Surg, 1-4-1 Inaho, Otaru, Hokkaido 0470032, Japan

[26] Wakayama Med Univ, Internal Med 3, 811-1 Kimiidera, Wakayama, 6418509, Japan

[27] Natl Hosp Org Shikoku Canc Ctr, Dept Breast Oncol, 160 Kou,Minamiumemoto Machi, Matsuyama, Ehime 7910280, Japan

[28] Gifu Univ Hosp, Dept Pharm, 1-1 Yanagido, Gifu 5011194, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 29卷 / 11期

关键词：

Antiemetics; Carboplatin; Chemotherapy-induced nausea and vomiting; Moderately emetogenic chemotherapy; Neurokinin-1 receptor antagonist; Systematic review and meta-analysis; DOUBLE-BLIND; BROAD RANGE; PHASE-II; APREPITANT; PREVENTION; EFFICACY; CANCER; DEXAMETHASONE; FOSAPREPITANT; PALONOSETRON;

D O I：

10.1007/s10147-024-02623-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundChemotherapy-induced nausea and vomiting (CINV) commonly affects patient quality of life and the overall effectiveness of chemotherapy. This study aimed to evaluate whether adding neurokinin-1 receptor antagonists (NK1RAs) to 5-hydroxytryptamine-3 receptor antagonists (5-HT3RAs) and corticosteroids provides clinically meaningful benefits in preventing CINV in patients receiving moderately emetogenic chemotherapy (MEC).MethodsWe conducted a systematic review of PubMed, Cochrane Library, and Ichushi-Web to identify clinical studies evaluating NK1RAs combined with 5-HT3RAs and dexamethasone for managing CINV in MEC. The endpoints were complete response (CR), complete control (CC), total control (TC), adverse events, and costs. The data were analyzed using a random effects model.ResultsFrom 142 articles identified, 15 randomized controlled trials (RCTs), involving 4,405 patients, were included in the meta-analysis. Approximately 60% of the patients received carboplatin (CBDCA)-based chemotherapy. The meta-analysis showed that triplet antiemetic prophylaxis with NK1RA was significantly more effective for achieving CR than doublet prophylaxis in each phase. Regarding CC, the triplet antiemetic prophylaxis was significantly more effective than the doublet in the overall (risk difference [RD]: 0.11, 95% confidence interval [CI]: 0.06-0.17) and delayed (RD: 0.08, 95% CI: 0.02-0.13) phases. For TC, no significant differences were observed in any phase. Adding NK1RA did not cause adverse events.ConclusionsAdding NK1RA to CBDCA-based chemotherapy has shown clinical benefits. However, the clinical benefits of NK1RA-containing regimens for overall MEC have not yet been established and require RCTs that exclusively evaluate MEC regimens other than CBDCA-based chemotherapy.

引用

页码：1616 / 1631

页数：16

共 50 条

[41] Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis
Ayer Botrel, Tobias Engel
Clark, Otavio Augusto C.
Clark, Luciana
Paladini, Luciano
Faleiros, Eneas
Pegoretti, Bruna
SUPPORTIVE CARE IN CANCER, 2011, 19 (06) : 823 - 832
[42] Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatments: Systematic review and meta-analysis
Clark, O.
Engel, T.
Clark, L.
Paladini, L.
Faleiros, E.
Pegoretti, B.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[43] Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis
Rezende Simino, Giovana Paula
Marra, Lays Pires
Gurgel de Andrade, Eli Iola
Acurcio, Francisco de Assis
Reis, Ilka Afonso
De Araujo, Vania Eloisa
Cherchiglia, Mariangela Leal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (09) : 1183 - 1194
[44] EFFICACY OF PALONOSETRON (PAL) COMPARED TO OTHER SEROTONIN INHIBITORS (5-HT3R) IN PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC (MOHE) TREATMENT: AN UPDATE OF THE PREVIOUSLY PUBLISHED SYSTEMATIC REVIEW AND META-ANALYSIS
Botrel, T. E. A.
Clark, O.
Clark, L. G. O.
Paladini, L.
Faleiros, E.
Pegoretti, B.
VALUE IN HEALTH, 2010, 13 (07) : A251 - A251
[45] Use of dexamethasone and a 5-HT3 receptor antagonist with or without aprepitant to prevent chemotherapy-induced nausea and vomiting among patients with lung cancer who are treated with platinum-based chemotherapy: a systematic review and meta-analysis of randomized controlled trials
He, Mengyu
Xu, Ruoxin
Liu, Miaowen
Zhang, Yixuan
Yi, Fengming
Wei, Yiping
Liu, Qing
Zhang, Wenxiong
ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (04) : 4308 - +
[46] Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology
Maeda, Tomoya
Najima, Yuho
Kamiyama, Yutaro
Nakao, Shinji
Ozaki, Yukinori
Nishio, Hiroshi
Tsuchihashi, Kenji
Ichihara, Eiki
Miumra, Yuji
Endo, Makoto
Maruyama, Dai
Yoshinami, Tatsuhiro
Susumu, Nobuyuki
Takekuma, Munetaka
Motohashi, Takashi
Ito, Mamoru
Baba, Eishi
Ochi, Nobuaki
Kubo, Toshio
Uchino, Keita
Kimura, Takahiro
Tamura, Shinobu
Nishimoto, Hitomi
Kato, Yasuhisa
Sato, Atsushi
Takano, Toshimi
Yano, Shingo
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (05) : 535 - 544
[47] Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology
Tomoya Maeda
Yuho Najima
Yutaro Kamiyama
Shinji Nakao
Yukinori Ozaki
Hiroshi Nishio
Kenji Tsuchihashi
Eiki Ichihara
Yuji Miumra
Makoto Endo
Dai Maruyama
Tatsuhiro Yoshinami
Nobuyuki Susumu
Munetaka Takekuma
Takashi Motohashi
Mamoru Ito
Eishi Baba
Nobuaki Ochi
Toshio Kubo
Keita Uchino
Takahiro Kimura
Shinobu Tamura
Hitomi Nishimoto
Yasuhisa Kato
Atsushi Sato
Toshimi Takano
Shingo Yano
International Journal of Clinical Oncology, 2024, 29 : 535 - 544
[48] Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology
Najima, Yuho
Maeda, Tomoya
Kamiyama, Yutaro
Nakao, Shinji
Ozaki, Yukinori
Nishio, Hiroshi
Tsuchihashi, Kenji
Ichihara, Eiki
Miumra, Yuji
Endo, Makoto
Maruyama, Dai
Yoshinami, Tetsuhiro
Susumu, Nobuyuki
Takekuma, Munetaka
Motohashi, Takashi
Ito, Mamoru
Baba, Eishi
Ochi, Nobuaki
Kubo, Toshio
Uchino, Keita
Kimura, Takahiro
Tamura, Shinobu
Nishimoto, Hitomi
Kato, Yasuhisa
Sato, Atsushi
Takano, Toshimi
Yano, Shingo
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, : 899 - 910
[49] Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022
Nozawa, Kazuki
Ozaki, Yukinori
Yoshinami, Tetsuhiro
Yokoe, Takamichi
Nishio, Hiroshi
Tsuchihashi, Kenji
Ichihara, Eiki
Miura, Yuji
Endo, Makoto
Yano, Shingo
Maruyama, Dai
Susumu, Nobuyuki
Takekuma, Munetaka
Motohashi, Takashi
Ito, Mamoru
Baba, Eishi
Ochi, Nobuaki
Kubo, Toshio
Uchino, Keita
Kimura, Takahiro
Kamiyama, Yutaro
Nakao, Shinji
Tamura, Shinobu
Nishimoto, Hitomi
Kato, Yasuhisa
Sato, Atsushi
Takano, Toshimi
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (08) : 1074 - 1080
[50] Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022
Ozaki, Yukinori
Yokoe, Takamichi
Yoshinami, Tetsuhiro
Nozawa, Kazuki
Nishio, Hiroshi
Tsuchihashi, Kenji
Ichihara, Eiki
Miura, Yuji
Endo, Makoto
Yano, Shingo
Maruyama, Dai
Susumu, Nobuyuki
Takekuma, Munetaka
Motohashi, Takashi
Ito, Mamoru
Baba, Eishi
Ochi, Nobuaki
Kubo, Toshio
Uchino, Keita
Kimura, Takahiro
Kamiyama, Yutaro
Nakao, Shinji
Tamura, Shinobu
Nishimoto, Hitomi
Kato, Yasuhisa
Sato, Atsushi
Takano, Toshimi
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (5) : 551 - 558

← 1 2 3 4 5 →